| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 06/30/2011 | US20110159098 Stabilization and delivery of nucleic acid complexes |
| 06/30/2011 | US20110159097 Extract of the plant ravenala madagascariensis and use as cosmetic hydrating agent |
| 06/30/2011 | US20110159096 1-(1H-1,2,4-Triazol-1-YL)Butan-2-OL Derivative For Pharmaceutical Use, and The Use Of a 1-(1H-1,2,4-Triazol-1-YL)Butan-2-OL Derivative With Substantially Undefined Crystal Shape For Preparing Said 1-(1H-1,2,4-Triazol-1-YL)Butan-2-OL Derivative |
| 06/30/2011 | US20110159095 Treatment of adrenal insufficiency |
| 06/30/2011 | US20110159094 Extended release compositions for high solubility, high permeability active pharmaceutical ingredients |
| 06/30/2011 | US20110159093 Modified release pharmaceutical compositions |
| 06/30/2011 | US20110159092 Extended release pharmaceutical composition comprising linezolid and process for preparing the same |
| 06/30/2011 | US20110159091 Rapidly dispersible vaginal tablet that provides a bioadhesive gel |
| 06/30/2011 | US20110159090 Abuse resistant drugs, method of use and method of making |
| 06/30/2011 | US20110159089 Abuse resistant drugs, method of use and method of making |
| 06/30/2011 | US20110159088 ORAL PHARMACEUTICAL FOR BASED ON AT LEAST ONE ACTIVE PRINCIPLE WHOSE SOLUBILITY VARIES AS A FUNCTION OF THE GASTRIC pH CONDITIONS |
| 06/30/2011 | US20110159087 Crosslinked Polymers |
| 06/30/2011 | US20110159086 Pharmaceutical formulation comprising a cb1-receptor compound in a solid solution and/or solid dispersion |
| 06/30/2011 | US20110159085 Abt-263 capsule |
| 06/30/2011 | US20110159084 Raloxifene pharmaceutical formulations |
| 06/30/2011 | US20110159083 Nanoparticles for protein drug delivery |
| 06/30/2011 | US20110159082 Pharmaceutical composition containing fenofibrate and method for the preparation thereof |
| 06/30/2011 | US20110159081 Vaccine |
| 06/30/2011 | US20110159080 Composition comprising liposome-entrapped doxorubicin and methods of administration |
| 06/30/2011 | US20110159079 High Delivery Rates for Lipid Based Drug Formulations, and Methods of Treatment Thereof |
| 06/30/2011 | US20110159078 Volatile Anesthetic Compositions and Methods of Use |
| 06/30/2011 | US20110159077 Pentoxifilin-based dermatological pharmaceutical composition, for topical application, in cream, gel, solution, emulsion, liposome and microcapsule form |
| 06/30/2011 | US20110159076 Autodestructive Transdermal Therapeutic System |
| 06/30/2011 | US20110159074 Wipe Article Comprising Lotion Composition Comprising Omega-6 Fatty Acid And Method Of Improving Skin Barrier Function |
| 06/30/2011 | US20110159072 Controlled release matrix |
| 06/30/2011 | US20110159070 Biomaterials and implants for enhanced cartilage formation, and methods for making and using them |
| 06/30/2011 | US20110159058 Film preparation containing loperamide hydrochloride |
| 06/30/2011 | US20110159057 Hydroxyapatite and bioglass-based pellets, production process and applications of thereof |
| 06/30/2011 | US20110159056 Methods and materials for stimulating proliferation of stem cells |
| 06/30/2011 | US20110159055 Nutritional supplement for use under physiologically stressful conditions |
| 06/30/2011 | US20110159054 Nanoparticulate bicalutamide formulations |
| 06/30/2011 | US20110159053 Preparation of a cell concentrate from a physiological solution |
| 06/30/2011 | US20110159052 Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
| 06/30/2011 | US20110159051 Composite for Thermo-Sensitive Cell-Tissue Transplanted Scaffold and Use thereof |
| 06/30/2011 | US20110159050 Amphiphilic proteins as morphology modifiers |
| 06/30/2011 | US20110159049 Pharmaceutical composition |
| 06/30/2011 | US20110159048 Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
| 06/30/2011 | US20110159047 Stable powder formulations of alum-adsorbed vaccines |
| 06/30/2011 | US20110159046 Controlled release formulations exhibiting an ascending rate of release |
| 06/30/2011 | US20110159045 Method of treating dysglycemia and glucose excursions |
| 06/30/2011 | US20110159044 Silver ion delivery platform |
| 06/30/2011 | US20110159039 Eliciting hcv-specific antibodies |
| 06/30/2011 | US20110158963 Three-dimensional matrices of structured porous monetite for tissue engineering and bone regeneration, and method of the preparation thereof |
| 06/30/2011 | US20110158960 Isolation of precursor cells and their use for tissue repair |
| 06/30/2011 | US20110158917 Anti-viral tissue product with visual efficacy indicator |
| 06/30/2011 | US20110158916 Anti-viral tissue product with visual indicator |
| 06/30/2011 | US20110158915 Nanoshells with targeted enhancement of magnetic and optical imaging and photothermal therapeutic response |
| 06/30/2011 | US20110156315 System and Method for Manufacturing a Medication |
| 06/30/2011 | CA2785991A1 Device and method for automatically opening and closing a material container during a lyophilization process |
| 06/30/2011 | CA2785643A1 Highly permeating terbinafine formulation for treating onychomycosis |
| 06/30/2011 | CA2785492A1 Lipids, lipid compositions, and methods of using them |
| 06/30/2011 | CA2785487A1 Solid pharmaceutical dosage form of ticagrelor |
| 06/30/2011 | CA2785468A1 Sustained release delivery devices |
| 06/30/2011 | CA2785434A1 Treatment for inflammatory bowel disease |
| 06/30/2011 | CA2785349A1 Combination therapy for copd |
| 06/30/2011 | CA2785347A1 Aerosol formulation for copd |
| 06/30/2011 | CA2785321A1 Combination therapy for copd |
| 06/30/2011 | CA2785317A1 Aerosol formulation for copd |
| 06/30/2011 | CA2785296A1 Combination composition useful for treating cardiovascular diseases |
| 06/30/2011 | CA2785254A1 Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue |
| 06/30/2011 | CA2785253A1 Calcipotriol monohydrate nanocrystals |
| 06/30/2011 | CA2785251A1 Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants |
| 06/30/2011 | CA2785249A1 Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture |
| 06/30/2011 | CA2785168A1 Swallowable drug delivery device and methods of drug delivery |
| 06/30/2011 | CA2785117A1 Transdermal therapeutic system for administering rivastigmine or derivatives thereof |
| 06/30/2011 | CA2785104A1 Topical ophthalmic peptide formulation |
| 06/30/2011 | CA2785021A1 Sustained-release formulation |
| 06/30/2011 | CA2784996A1 Formulation comprising 1 h-quinazoline-2,4-dione ampa receptor antagonists, in the form of immediate release tablets and preparation thereof |
| 06/30/2011 | CA2784849A1 Amphiphilic polymer functionalised by methionine |
| 06/30/2011 | CA2784179A1 Emulsion composition |
| 06/30/2011 | CA2780177A1 Abt-263 capsule |
| 06/30/2011 | CA2780080A1 Pharmaceutical compositions comprising igf-1 proteins, a buffering and a tonicity agent |
| 06/30/2011 | CA2767068A1 Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
| 06/30/2011 | CA2689400A1 Therapeutic agent delivery apparatus and process |
| 06/29/2011 | EP2339003A2 APO-2 ligand substitutional variants |
| 06/29/2011 | EP2338525A2 Remote detection of substance delivery to cells |
| 06/29/2011 | EP2338519A1 Agent for treating myelofibrosis |
| 06/29/2011 | EP2338512A1 Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| 06/29/2011 | EP2338497A1 Treatment and prevention of heat shock protein-associated diseases and conditions |
| 06/29/2011 | EP2338491A2 Pharmaceutical composition comprising a beta-carboline |
| 06/29/2011 | EP2338487A1 Combination therapy with PARP inhibitors |
| 06/29/2011 | EP2338480A1 Coating of particles comprising a pharmaceutically active ingredient with a carbonate salt or phosphate salt |
| 06/29/2011 | EP2338479A1 Radioactively marked microparticles, method for their manufacture and application thereof |
| 06/29/2011 | EP2338478A1 Method for producing liposomes |
| 06/29/2011 | EP2338477A1 Suppository comprising pantoprazole |
| 06/29/2011 | EP2338476A1 Suppository for rectal, vaginal or urethral administration containing a probiotic, an antibiotic and an unsaturated non-esterified fatty acid |
| 06/29/2011 | EP2338475A2 Treating canker sores with patches to speed healing and relieve pain |
| 06/29/2011 | EP2338474A1 Fusion tablet containing compacted sildenafil base |
| 06/29/2011 | EP2338473A1 Pharmaceutical dosage forms of tizanidine and administration routes thereof |
| 06/29/2011 | EP2338332A2 Hollow glucan particle or cell wall particle encapsulating a terpene component |
| 06/29/2011 | EP2338330A1 Antimicrobial composites, films, labelstocks and labels |
| 06/29/2011 | EP2337580A1 New protecting compositions for recombinantly produced factor viii |
| 06/29/2011 | EP2337567A1 Veterinary preparation |
| 06/29/2011 | EP2337565A1 Stable solid oral dosage co-formulations |
| 06/29/2011 | EP2337563A1 Modulators of aldehyde dehydrogenase activity and methods of use thereof |
| 06/29/2011 | EP2337561A1 Use of tocotrienol composition for the prevention of cancer |
| 06/29/2011 | EP2337557A2 Anhydrous antiperspirant compositions |
| 06/29/2011 | EP2231120B1 Solid lipid microcapsules containing growth hormone in the inner solid core |
| 06/29/2011 | EP2217253B1 Bifidobacterium for dust mite allergy |
| 06/29/2011 | EP2121479B1 Complementary personal lubricant compositions delivery system |